Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Study Identifier:
M11-001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
Date
Apr 2012 - Jan 2031
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
Date
Apr 2012 - Jan 2031
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Trial Locations
Location
Status
Location
Clinical Trial Site
Aurora, Colorado, United States, 80045
Status
Recruiting
Location
Clinical Trial Site
Washington, District of Columbia, United States, 20007
Status
Recruiting
Location
Clinical Trial Site
Gainesville, Florida, United States, 32610
Status
Recruiting
Location
Clinical Trial Site
Atlanta, Georgia, United States, 30322
Status
Recruiting
Location
Clinical Trial Site
Chicago, Illinois, United States, 60614
Status
Withdrawn
Location
Clinical Trial Site
Boston, Massachusetts, United States, 02115
Status
Recruiting